CL2019003635A1 - Composiciones y tratamientos para el trastorno del sueño. - Google Patents

Composiciones y tratamientos para el trastorno del sueño.

Info

Publication number
CL2019003635A1
CL2019003635A1 CL2019003635A CL2019003635A CL2019003635A1 CL 2019003635 A1 CL2019003635 A1 CL 2019003635A1 CL 2019003635 A CL2019003635 A CL 2019003635A CL 2019003635 A CL2019003635 A CL 2019003635A CL 2019003635 A1 CL2019003635 A1 CL 2019003635A1
Authority
CL
Chile
Prior art keywords
extract
cannabis
treatments
compositions
sleep disorder
Prior art date
Application number
CL2019003635A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Patrizia Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902338A external-priority patent/AU2017902338A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2019003635A1 publication Critical patent/CL2019003635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN EXTRACTO DE CANNABIS Y OPCIONALMENTE UNO O MÁS PORTADORES, DILUYENTES, ADYUVANTES, EXCIPIENTES O CUALQUIER COMBINACIÓN DE LOS MISMOS FARMACÉUTICAMENTE ACEPTABLES, EL EXTRACTO DE CANNABIS COMPRENDE UNA FRACCIÓN DE CANNABINOIDES QUE COMPRENDE Δ 9 -TETRAHIDROCANNABINOL (THC), CANNABIDIOL (CBD) Y CANNABINOL (CBN) Y UNA FRACCIÓN DE TERPENOS EN UNA CANTIDAD DE AL MENOS 3 % EN PESO DEL EXTRACTO. LA INVENCIÓN TAMBIÉN SE REFIERE A MÉTODOS PARA TRATAR TRASTORNOS DEL SUEÑO MEDIANTE EL USO DE ESTA COMPOSICIÓN FARMACÉUTICA.
CL2019003635A 2017-06-19 2019-12-12 Composiciones y tratamientos para el trastorno del sueño. CL2019003635A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017902338A AU2017902338A0 (en) 2017-06-19 Sleep Disorder Composition and Treatment Thereof
AU2017904818A AU2017904818A0 (en) 2017-11-29 Sleep Disorder Compositions and Treatments Thereof

Publications (1)

Publication Number Publication Date
CL2019003635A1 true CL2019003635A1 (es) 2020-06-19

Family

ID=62947713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003635A CL2019003635A1 (es) 2017-06-19 2019-12-12 Composiciones y tratamientos para el trastorno del sueño.

Country Status (16)

Country Link
US (2) US20210145910A1 (es)
EP (1) EP3641754A4 (es)
JP (1) JP2020524151A (es)
KR (1) KR20200104278A (es)
CN (1) CN110944632A (es)
AU (2) AU2018100837B4 (es)
BR (1) BR112019026877A2 (es)
CA (1) CA3065563C (es)
CL (1) CL2019003635A1 (es)
CO (1) CO2019013887A2 (es)
IL (1) IL271503A (es)
MX (1) MX2019015315A (es)
NZ (1) NZ759963A (es)
PE (1) PE20201163A1 (es)
SG (1) SG11201912380XA (es)
WO (1) WO2018232448A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
NL2022616B1 (en) * 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US10946054B1 (en) * 2019-10-08 2021-03-16 Jenny's Rose, LLC Therapeutic cannabis extracts
US20220071946A1 (en) * 2020-03-03 2022-03-10 Alte Verde Llc Cannabis Treatment of Insomnia, Pain, and Skin Conditions
WO2021181248A1 (en) * 2020-03-09 2021-09-16 This Works Products Limited Compositions comprising functional fragrances and cannabis-derived compounds
CN112057894A (zh) * 2020-09-08 2020-12-11 云南工麻生物科技有限公司 一种提取大麻二酚的方法
CN113143995A (zh) * 2021-01-21 2021-07-23 龙麻(上海)医药研发有限责任公司 一种大麻提取物舌下片及其制备工艺和应用
CN112999218A (zh) * 2021-01-21 2021-06-22 龙麻(上海)医药研发有限责任公司 一种具有镇静助眠功效的组合物及用途
CN112791151B (zh) * 2021-02-20 2022-04-01 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
DK181329B1 (en) 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
WO2022261662A1 (en) * 2021-06-09 2022-12-15 Demetrix, Inc. Regulation of the sleep/wake cycle using cannabinoid compounds
AU2023212130A1 (en) * 2022-01-27 2024-05-23 DEFINED RESEARCH, Inc. A cannabidiol (cbd) and terpene formulation that increases restorative sleep in humans

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
EP3007714A1 (en) * 2013-06-13 2016-04-20 Cannabis Science International Holding BV Composition for the treatment of neurobehavioral disorders
CN103355391A (zh) * 2013-08-13 2013-10-23 汕头大学医学院第一附属医院 一种五味健脑益智饼及其制备方法
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
AU2016267585C1 (en) * 2015-05-28 2023-02-16 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
MX2019001285A (es) * 2016-08-03 2019-06-13 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis.
US9649349B1 (en) * 2017-01-19 2017-05-16 Metamorphic Alchemy & Distillations, Inc. System and method for producing a terpene-enhanced cannibinoid concentrate
WO2018173049A1 (en) * 2017-03-20 2018-09-27 Kanabo Research Ltd. Vaporizable compositions comprising cannabinol
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
US11202771B2 (en) * 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder

Also Published As

Publication number Publication date
CO2019013887A2 (es) 2020-04-01
US20210145910A1 (en) 2021-05-20
WO2018232448A1 (en) 2018-12-27
BR112019026877A2 (pt) 2020-06-30
MX2019015315A (es) 2020-02-17
IL271503A (en) 2020-02-27
KR20200104278A (ko) 2020-09-03
AU2018286647B2 (en) 2024-03-28
EP3641754A4 (en) 2021-03-10
PE20201163A1 (es) 2020-10-28
SG11201912380XA (en) 2020-01-30
AU2018100837B4 (en) 2019-02-21
NZ759963A (en) 2022-07-01
AU2018286647A1 (en) 2020-01-16
US20230270808A1 (en) 2023-08-31
AU2018100837A4 (en) 2018-07-26
CA3065563C (en) 2023-06-13
JP2020524151A (ja) 2020-08-13
CN110944632A (zh) 2020-03-31
EP3641754A1 (en) 2020-04-29
CA3065563A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
PE20230607A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
CL2019000268A1 (es) Composición de cannabis.
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
ECSP18082774A (es) Derivados aromáticos de sulfonamida
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
GT201400111A (es) Triazolopiridinas sustituidas
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
BR112017011440A2 (pt) uma composição antimicrobiana
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
ECSP22021881A (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso